Pharmaceuticals 2010, 3(5), 1311-1334; doi:10.3390/ph3051311
Review

Prospects for the Use of ATR Inhibitors to Treat Cancer

Division of Oncology Research, College of Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA
* Author to whom correspondence should be addressed.
Received: 31 March 2010; in revised form: 12 April 2010 / Accepted: 19 April 2010 / Published: 28 April 2010
(This article belongs to the Special Issue Protein Kinase Inhibitors)
PDF Full-text Download PDF Full-Text [240 KB, uploaded 28 April 2010 10:08 CEST]
Abstract: ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.
Keywords: Replication checkpoint; ATR; ATM; chemotherapy; Chk1

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Wagner, J.M.; Kaufmann, S.H. Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals 2010, 3, 1311-1334.

AMA Style

Wagner JM, Kaufmann SH. Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals. 2010; 3(5):1311-1334.

Chicago/Turabian Style

Wagner, Jill M.; Kaufmann, Scott H. 2010. "Prospects for the Use of ATR Inhibitors to Treat Cancer." Pharmaceuticals 3, no. 5: 1311-1334.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert